CDKN2A and central nervous system cancer: Few studies focus on the association between p16 IHC and CDKN2A deletion in glioma samples [12,13,14,15], but, with respect to IDH-mutant astrocytomas, some have reported a significant association between p16-negative IHC and a high negative predictive value.